Wei Ren outlines options, RSUs and shares in ASCENTAGE PHARMA (AAPG) Form 3

Rhea-AI Filing Summary

ASCENTAGE PHARMA GROUP INTERNATIONAL director Wei Ren has filed an initial ownership report on Form 3, detailing current equity holdings in the company. The filing shows stock options over 18,850 Ordinary Shares at an exercise price of $8.1400 per share, expiring on November 26, 2035. These options vest in twelve equal monthly tranches starting on November 26, 2025.

Ren also holds restricted share units (RSUs) linked to 28,850 Ordinary Shares, which vest in four equal increments on each of November 26, 2026, 2027, 2028 and 2029. In addition, the filing lists direct ownership of 8,964 Ordinary Shares as of the reported date, providing a clear picture of Ren’s existing economic stake and unvested awards.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wei Ren

(Last) (First) (Middle)

700 KING FARM BLVD, STE 510

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	8,964	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	11/26/2035	Ordinary Shares	18,850	$8.14(2)	D
Restricted share units	(3)	(3)	Ordinary Shares	28,850	$0	D

Explanation of Responses:

1. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025.

2. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant.

3. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029.

Remarks:

This form is filed using a special power of attorney.

	Thomas J. Knapp	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Wei Ren’s Form 3 filing show for ASCENTAGE PHARMA (AAPG)?

Wei Ren’s Form 3 shows existing equity holdings in ASCENTAGE PHARMA, not new trades. It lists stock options, restricted share units tied to Ordinary Shares, and directly held Ordinary Shares, outlining his current economic stake and future vesting awards with specific dates and terms.

How many stock options does Wei Ren report in ASCENTAGE PHARMA (AAPG)?

Wei Ren reports stock options over 18,850 Ordinary Shares in ASCENTAGE PHARMA. These options carry an exercise price of $8.1400 per share, converted from HKD, and expire on November 26, 2035, vesting in twelve equal monthly tranches starting in late 2025.

What restricted share units (RSUs) does Wei Ren hold in ASCENTAGE PHARMA (AAPG)?

Wei Ren holds RSUs representing 28,850 underlying Ordinary Shares of ASCENTAGE PHARMA. Each RSU converts into one Ordinary Share upon vesting, with vesting in four equal installments on November 26, 2026, 2027, 2028 and 2029, indicating a multi-year incentive structure.

How many ASCENTAGE PHARMA (AAPG) Ordinary Shares does Wei Ren own directly?

The Form 3 lists direct ownership of 8,964 Ordinary Shares by Wei Ren. This figure reflects his current direct equity position separate from unexercised options and unvested RSUs, giving investors insight into his immediate share exposure in the company.

Did Wei Ren buy or sell ASCENTAGE PHARMA (AAPG) shares in this Form 3?

The Form 3 does not report any buys or sells; it is an initial ownership statement. It simply records Wei Ren’s existing stock options, RSUs and directly held Ordinary Shares as of the reported date, without indicating any new market transactions.

How do Wei Ren’s options and RSUs in ASCENTAGE PHARMA (AAPG) vest over time?

Wei Ren’s stock options vest in twelve equal monthly tranches starting on November 26, 2025. His RSUs vest in four equal increments on November 26, 2026, 2027, 2028 and 2029, spreading potential share delivery across several years.